Atopic Dermatitis Drugs Market Size is Expected to Reach $6.41 Billion by 2022| Key Industry Participants Mylan, Pfizer

San Francisco, 5 November 2018: The global atopic dermatitis drugs market size is expected to reach USD 6.41 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.6% during the forecast period. Various factors such as emergence of novel therapeutics and growing uptake of targeted therapies are stimulating the growth of the market.

Eucrisa (Pfizer; crisaborole ointment) was approved by the U.S. FDA for treatment of atopic dermatitis (AD), in 2016. The drug is indicated for mild-to-moderate AD in patients who are two years or older, meeting a key therapeutics need of the market. Dupixent (Sanofi/Regeneron) was the first biologic to be launched in 2017 for management of AD. The drug is under clinical investigation for use in pediatric population.

Several promising candidates, especially biologics and small molecules, in pipeline are expected to alter the AD therapeutic landscape post launch. Nemolizumab is anticipated to be the first biologic (anti-IL-13) indicated for itching associated with atopic dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for safety and efficacy of treatment of moderate-to-severe AD.

Upcoming patent expiration of key products, such as LEO Pharma’s Protopic, Mylan/Valeant’s Elidel, and Bayer’s Desonate will result in generic penetration in therapeutic space. However, novel therapeutics, such as Eucrisa and Dupixent, are likely to gain traction over the forecast period and attain blockbuster status.

Underdeveloped and unserved categories such as rarer subtypes and pediatric population offer strong commercial opportunities. Drug companies are currently investigating multiple treatment options in niche indications such as severe refractory atopic dermatitis. Improving availability of new treatment modalities and targeted approaches offer a promising future for the global atopic dermatitis drugs market.

Access Research Report of Atopic Dermatitis Drugs Market @ www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market

Further key findings from the report suggest:

·       Corticosteroids dominated the drug class in 2016, owing to their indication as first-line therapeutics for atopic dermatitis

·       Recent launch of biologics and small molecules such as Dupixent and Eucrisais likely to change the current therapeutic scenario due to their target-oriented mechanism of action

·       Calcineurin inhibitors are likely to witness stifled growth because of adverse effects, non-specificity, and development of resistance to chemical agents

·       The U.S. was the leading regional market in 2016. It is posed to maintain its position through 2022, owing to burgeoning disease burden, increasing treatment rate, and high drug cost

·       The topical segment led the atopic dermatitis drugs market in 2016, based on route of administration. Although the segment is expected to continue leading the market through 2022, Dupixent’s launch in 2017 marked the arrival of injectable. The new RoA is anticipated to hold approximately 30.0% market share by 2022

·       Bayer, LEO Pharma, Mylan, Pfizer, and Sanofi are some of key players operating in the market

·       Pfizer and Sanofi are anticipated to be leaders in AD therapeutic space by 2022 due to growing adoption of targeted therapies, such as Eucrisa and Dupixent

·       Rarer subtypes, such as severe refractory atopic dermatitis, have few treatment options available and lack a significant pipeline. This field presents a strong commercial opportunity to drug developers.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global atopic dermatitis drugs market based on drug class, route of administration, and region:

Atopic Dermatitis Drugs Class Outlook (Revenue, USD Million, 2016 - 2022)

·         Corticosteroids

·         Calcineurin Inhibitors

·         PDE4 Inhibitors

·         Biologics

·         Others

Atopic Dermatitis Drugs Route of Administration Outlook (Revenue, USD Million, 2016 - 2022)

·         Topical

·         Injectable

·         Oral

Atopic Dermatitis Drugs Regional Outlook (Revenue, USD Million, 2016 - 2022)

·         U.S.

·         U.K.

·         Germany

·         Spain

·         France

·         Italy

·         Japan

Access Press Release of Atopic Dermatitis Drugs Market@ www.grandviewresearch.com/press-release/global-atopic-dermatitis-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Organic Seed Market to Surpass $4.59 Billion by 2022| Top Industry Players Fleuren, Johny

San Francisco, 2 November 2018: The global organic seed market is expected to reach USD 4.59 billion by 2022, according to a new report by Grand View Research, Inc. Growing health consciousness and environmental awareness have resulted in shift in consumer preferences towards organic food. Such trends are projected to complement the organic seed market in the near future. Organic food products are devoid of any chemical exposure and are thus healthier than their conventional counterparts. Rising disposable income and increasing market penetration are key factors that are expected to aid the organic seed market particularly in the emerging markets of Asia Pacific and Central & South America. 

High organic seed cost is anticipated to act as a major deterrent for market growth and development. Lack of awareness, high demand-supply imbalance and lower awareness regarding organic food products are some other challenges faced by market participants. Unavailability of high quality and certified organic seeds is another prominent factor that is anticipated to negatively impact the regional as well as global market over the next seven years. Technological advancements, better value chain management and wide distribution network are a few areas which offer ample growth opportunities to the industry participants over the forecast period. 

Access Research Report of Organic Seed Market@ www.grandviewresearch.com/industry-analysis/organic-seeds-market

Further key findings from the report suggest:

·       Global organic seed market was valued at USD 1,698.5 million in 2014 and is expected to be valued at USD 4,593.6 million in 2022, growing at an estimated CAGR of 13.6% from 2014 to 2022.

·       Vegetable seeds dominated the global market and accounted for over 30% of total revenue in 2014. They are also expected to witness the highest growth rate over the forecast period.

·       North America dominated the global organic seed market with demand share estimated at 35.7% in 2014. Asia Pacific is projected to witness the highest growth of 14.3% from 2015 to 2022. Growing awareness regarding benefits offered by organic seed particularly in China and India is expected to drive the regional market over the forecast period.  

·       The industry is segmented and is characterized by high industry rivalry owing to the presence of numerous industry participants. Region specific organic seed producers play a critical role across the value chain. There is considerable supply-demand gap which has arisen due to the brisk growth in demand for organic food products in the recent past.

·       Key industry participants operating in the global market include Seed Savers Exchange, Wild Garden Seeds, Fleuren, Johny;s Selected Seeds, Navdanya, Maas Plant, Seeds of Change, Fedco Seeds and Vitalis Organic Seeds.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/nutraceuticals-functional-foods-and-dietary-supplements

Grand View Research has segmented the organic seed market on the basis of product and region:

Global Organic Seed Product Outlook (Revenue, USD Million, 2012 - 2022)

·         Vegetable Seeds

·         Field Crop Seeds

·         Fruit & Nuts

·         Other Vegetation

Global Organic Seed Regional Outlook (Revenue, USD Million, 2012 - 2022)

·         North America

·         Europe

·         Asia Pacific

·         Central & South America

·         Middle East & Africa

Access Press Release of Organic Seed Market@ www.grandviewresearch.com/press-release/global-organic-seed-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Insulin Delivery Devices Market is Expected to Reach $19.8 Billion by 2025| Top Industry Players Eli Lilly and Company; Medtronic

San Francisco, 2 November 2018: The insulindelivery devices market is expected to reach USD 19.8 billion by 2025, according to a new report by Grand View Research, Inc. The global industry is estimated to witness a high growth during the forecast period from 2016 to 2025. Rapidly increasing number of diabetics coupled with the escalating attention around diabetes care is a major factor propelling the market.

Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes. In addition, growing diabetic geriatric population is another factor supporting the growth of this vertical. According to the United Nations, Department of Economic and Social Affairs, around 901 million individuals were aged 60 or over in 2015 and this number is projected to increase to 1.4 billion by 2030. Thus, the enlarging elderly population is expected to boost the demand for insulin delivery devices. 

Technological innovations and advancements are an ongoing trend in this vertical. Also, favorable reimbursement policies for these devices, mainly in developed countries like the U.S. and Germany, are anticipated to fuel the market growth during the study period. However, stringent regulatory requirements regulating the approval of insulin delivery devices is a major factor restraining the growth of this industry.

Access Research Report of Insulin Delivery Devices Market @ www.grandviewresearch.com/industry-analysis/insulin-delivery-devices-market

Further Key Findings from the Study Suggest:

·       The insulin pens segment was the largest revenue-generating category of this market in 2015. The pen is equipped with self-contained cartridges and offers ease in handling & less pain while injecting insulin. Advantages of these pen devices over other products are resulting in its growing popularity, thus serving as a vital factor in contributing to the sector’s highest share in this market.

·       Homecare is estimated to be the largest shareholder and the fastest growing segment due to increased adoption of self-care diabetes management devices and the availability of simplified and user-friendly product designs for patients.

·       North America is the leading regional sector and accounted for the largest revenue share in 2015 primarily due to the favorable reimbursement scenario in this space. Also, the presence of major manufacturers in this region is supporting the market growth. 

·       The Asia Pacific region is anticipated to be the fastest growing market during the forecast period. The high prevalence rate of diabetes in the Asian countries, such as China and India, is a major factor contributing to market expansion in this region.

·       Some key players serving this vertical include Novo Nordisk A/S; Sanofi; Eli Lilly and Company; Medtronic; Becton, Dickinson and Company; Abbott; and F. Hoffmann-La Roche Ltd. 

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the insulin delivery devices market on the basis of product, end-use, and region:

Insulin Delivery Devices Market Product Outlook (Revenue, USD Million, 2014 - 2025)

·         Insulin syringes

·         Insulin pens

·         Insulin pumps

·         Insulin injectors

Insulin Delivery Devices End-use Outlook (Revenue, USD Million, 2014 - 2025)

·         Hospitals

·         Home care

·         Others            

Insulin Delivery Devices Market Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

·          Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Access Press Release of Insulin Delivery Devices Market@ www.grandviewresearch.com/press-release/global-insulin-delivery-devices-market-analysis

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Monoclonal Antibodies (mAbs) Market Set to Record Exponential Growth by 2024|Key Industry Participants Novartis AG, Merck & Co., Inc

San Francisco, 2 November 2018: The global monoclonalantibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.

Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing toward significant market growth.

In addition, the government initiatives to enable cost-effective production of mAbs is anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative byNational Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.

Access Research Report of Monoclonal Antibodies (mAbs) Market @ www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market

Further Key Findings from the Study Suggest:

·       Human-based mAbs segment is predicted to grow at a lucrative CAGR in the coming years due to their associated benefits and numerous R&D activities conducted for further development of human mAbs. Large number of mAbs of human origin are in phase III clinical trial for cancer treatment

·       In vitro production of mAbs is anticipated to show the fastest growth owing to its wide-scale adoption by biologics manufacturers due to its greater efficiency in cost and time

·       The research institute segment is anticipated to exhibit profitable growth due to increasing R&D efforts in the biotech industry as monoclonal antibodies have emerged as a major class of therapeutics for several human diseases, particularly immunological infectious diseases and cancer

·       The Asia pacific region has significant growth potential due to rising government initiatives in this region supporting the use of mAbs for research and treatment purposes coupled with the surge in sponsored R&D projects for the development of cost-effective therapeutic mAbs.

·       For instance, government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct mAb research and development.

·       The key players serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.

·       The introduction of advanced methods for mAb production further encourages the pharmaceutical companies to build their own product pipeline. According to a study published by NCBI at the end of 2013, approximately 816 companies were involved in therapeutic protein research. 

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the monoclonal antibodies market by source type, production, indication, end-use, and region:

Global Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024)

·         Murine

·         Chimeric

·         Humanized

·         Human 

Global Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024)

·         In Vivo

·         In Vitro

Global Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024)

·         Cancer

·         Autoimmune Diseases

·         Inflammatory Diseases

·         Infectious Diseases

·         Microbial Diseases

·         Others

Global Monoclonal Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024)

·         Hospitals

·         Research Institutes

·         Others

Monoclonal antibodies Market Regional Outlook (Market Revenue in USD Billion, 2013 - 2024)

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Access Press Release of Monoclonal Antibodies (mAbs) Market@ www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Marketing Automation Software Market is Expected to Reach $7.63 Billion by 2025| Key participants HubSpot, Inc., IBM Corporation

San Francisco, 2 November 2018: According to a report published by Grand View Research, Inc.; marketingautomation software market is expected to reach a valuation of around USD 7.63 billion by 2025.

Increasing demand for the software for customer lifecycle marketing, lead generation management, and customer retention can propel the market over the forecast period (2014 to 2025).

The software help organizations to automate repetitive tasks such as emails, social media, and several other website functions to save time, efforts, and costs. Increasing acceptance of SaaS model and growing dependency on social media for information is expected to promote the demand for this software. Consumers across the world have transformed traditions of perceiving information and exploring products and services before purchase. Consumers have become tech-savvy and highly dependent on information available on social media sites, blogs, search engines. This has encouraged companies to develop strong consumer relationship interface that can offer better experience. The solutions are extensively implemented across the business to business (B2B) as well as business to consumer (B2C) business models. The B2B industries such as software, manufacturing and business services were the early adopters of the technology. But, the technology is increasingly implemented in B2C industries including media and entertainment, financial services, retail, and healthcare.

Worldwide marketing automation market can be segmented on the basis of solution, enterprise size, deployment, application, and region.

Access Research Report of Marketing Automation Software Market@ www.grandviewresearch.com/industry-analysis/marketing-automation-software-market

Based on solution, the market can be segmented on the basis of campaign management, inbound marketing, email marketing, lead management, mobile applications, social media marketing, reporting and analytics, and others.

In 2015, the email marketing segment estimated for 30% of the overall market share. But, the reporting and analytics segment is anticipated to grow at the highest CAGR of 13.3% during the forecast period. This technology is expected to be useful in manufacturing and expected to expand at an estimated CAGR of 11.88% during 2016 to 2025.

As per enterprise size, the market can be classified into small and mid-sized enterprises (SME) and large enterprise. Earlier the use of technology was limited to large enterprisers. However, the SME segment is expected to be the largest segment due to increasing adoption of the technology

On the basis of deployment, the market can be bifurcated into cloud and on-premises.

The cloud segment is expected to dominate during the forecast period due to its cost effectiveness as it eliminates the hardware installations. This deployment type also helps to improve customer interaction by providing accessibility of single source of information to organization.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/emerging-and-next-generation-technologies

Based on application, the market can be split into BFSI, government and education, retail, telecom and IT, healthcare, discrete manufacturing, and others.

In 2015, the telecom and IT segment together estimated over 23% of overall market revenue. Though, the discrete manufacturing segment is projected to expand at the highest CAGR during the forecast period.

Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In 2015, North America estimated for the major revenue share of around 54% of the overall market. This growth can be credited to existence of numerous leading companies in the U.S.

Asia Pacific is projected to expand at a CAGR of 13.5% during 2016 to 2025.  Strong economic growth in developing countries such as India and China, which hold a huge customer base is expected to support the market growth in this region.  In addition, presence of diversity in culture, politics, and economic is also expected to boost the product demand as these factors are more critical to understand customer behavior. Due to these factors companies in this region are struggling to increase their customer retention and loyalty levels. This is also expected to increase the product demand to avoid additional expenses.

Some of the leading companies operating in the market include Act-On Software, Inc.; IBM Corporation; Adobe systems, Inc.; Salesforce.com, Inc., and HubSpot, Inc.

The market is extremely competitive and concentrated. Market participants are increasingly focusing on expansion of their product and service portfolios.

Access Press Release of Marketing Automation Software Market@ www.grandviewresearch.com/press-release/global-marketing-automation-software-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com